The OS differences were nonsignificant with the exception of a beneficial outcome for the immunotherapy combination in patients with tumor PD-L1 expression scores between 1 and 49 (HR = 0.41 [95% CI: 0.20–0.83, p = 0.010]) (Supplementary Table 1 and Supplementary Fig. 3). The gene discussed is CD274; the disease is neoplasm.